Memory Compound definition

Memory Compound means any PDE4 inhibitor for which Memory either prior to the Effective Date or during the Agreement Term has rights, whether by reason of its own conception of such inhibitor, or under agreement with a Third Party.
Sample 1Sample 2
Memory Compound means any compound which is a nicotinic alpha-7 agonist with respect to which (i) Memory has commenced a Phase I human clinical trial within five (5) years after the Effective Date or (ii) Roche has designated pursuant to Section 2.2 or Section 4.6 hereof.
Sample 1Sample 2
Memory Compound means any compound which is a nicotinic alpha-7 agonist [*] (a) (i) the composition of matter of which is Covered in the United States by any of the Memory Patent Rights as of the Effective Date or (ii) that is listed in a letter of even date from Memory to Roche and (b) demonstrated by either Party to have Threshold Activity prior to the Effective Date or during the Extended Period provided that Compound 3454 is not a Memory Compound.
Sample 1

Examples of Memory Compound in a sentence

  • If Roche is required by a relevant government authority in a given country of the Territory to divest rights to a Memory Compound and/or Product with respect to which Roche has not commenced the Initiation of Phase III, then Roche shall use its reasonable best efforts to obtain authority to fulfill such requirement by returning rights to Memory to the Memory Compound and/or Product in accordance with Section 16.5.

  • Memory represents and warrants that as of the Effective Date, to its actual knowledge of its senior executives, after consultation with patent counsel, there is no issued patent right owned or controlled by any Third Party which Covers the lead compounds of the Program identified by Memory to Roche and would prevent Roche from selling such Memory Compound in any country of the Territory.

  • Memory represents and warrants that as of the Effective Date, to its actual knowledge of its senior executives, after consultation with patent counsel, there is no issued patent right owned or controlled by any Third Party which Covers the lead compound identified by Memory to Roche (MEM1414) and would prevent Roche from selling such Memory Compound in any country of the Territory.

  • The goal of the Research Collaboration shall be to (1) deliver to Roche an IND package for the lead Memory Compound MEM1414 and (2) identify back-up and follow-up Memory Compounds and Collaboration Compounds for MEM1414, and identify a lead compound for depression, as well as back-up compounds.

  • Notwithstanding the above, Memory shall supply Memory Compound designated as 63908 for purposes of conducting Phase I studies with respect thereto, and Roche shall have no obligation to reimburse Memory for the cost of manufacture.

  • Notwithstanding anything to the contrary, payment shall be made pursuant to this Section 5.9 with respect to a Product for a Neurological Indication or a Psychiatric Indication only if such Product contains a different Memory Compound than any Memory Compound contained in a Product for which payment previously has been made pursuant to this Section 5.9.

  • As of the Effective Date, to the actual knowledge of its senior executives, after consultation with in-house patent counsel (who shall have undertaken due inquiry), there is no issued patent right owned or controlled by any Third Party which would be infringed by the making, using, selling or importing of the series of compounds identified by Memory to Amgen on Schedule 1.65 or would prevent Amgen from selling such Memory Compound in any country of the Territory.

  • Watanabe, Field-Induced Martensitic Transformation in New Ferromagnetic Shape Memory Compound Mn1.07Co0.92Ge, Jpn.

  • Memory shall have the right to deduct a maximum of [*] percent ([*]%) of the consideration actually paid by Memory or its Affiliate to a Third Party with respect to a license under a patent which Covers an NPS Compound or Memory Compound, from payments otherwise due and payable by Memory to NPS under this Agreement.

  • Not to forget the group of people with disability who almost always be in needing of assistance with their daily activities.


More Definitions of Memory Compound

Memory Compound means any 5-HT6 receptor antagonist for which Memory as of the Effective Date or during the term of this Agreement has rights, by reason of its own conception of such antagonist, and are Covered by Memory Patent Rights, but are not covered by the NPS Patent Rights. A list of the Memory Compounds is set forth in Schedule A hereto, as shall be updated from time-to-time.
Sample 1
Memory Compound means any PDE10 inhibitor or modulator for which Memory during the Agreement Term has rights, whether by reason of its own conception of such inhibitor or modulator or under agreement with a Third Party, which is Covered by a Valid Claim of a Memory Patent Right.
Sample 1

Related to Memory Compound

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Licensed Compound means a TAK-385 Licensed Compound or a TAK-448 Licensed Compound.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Compounds means any or all of the following chemicals, as the context requires:

  • Product Candidate means each biological and drug candidate, compound or other device or product being developed, labeled, manufactured, marketed, sold and/or distributed by the Company or a Company Subsidiary, or regarding which the Company or a Company has rights, and including any such biological and drug candidate, compound or product that has received Marketing Approval.

  • Diagnostic Product means an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Nicotine product means the same as that term is defined in Section 76-10-101.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications, or derivatives thereof, but excluding single variable domains (heavy or light) of such antibodies.

  • Competing Product means [***].

  • Biological Samples means any physical samples obtained from Study Participants in accordance with the Protocol for the purposes of the Study.

  • medicinal product means any substance or combination of substances presented for treating or preventing disease in human beings or animals and any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans or in animals;

  • Exempt compound means the same as defined in Rule 2.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Program Technology means Program Know-How and Program Patents.

  • Licensed Product means any pharmaceutical product containing a Licensed Compound (alone or with other active ingredients), in all forms, presentations, formulations and dosage forms.

  • Program Patent Rights means any Patent Rights that contain one or more claims that cover Program Inventions.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Phase I Study means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. § 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof.